Evaluation the effects of Vitamin E and selenium on the expression of nox5 and HSPA2 in infertile men

Evaluation the effects of Vitamin E and selenium on the expression of nox5 and HSPA2 in astheniteratozoospermia men

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140409017210N2

Enrollment

Registered

2021-06-04

Start date

2014-06-22

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertile asthenoteratozoospermia men. Diseases of male genital organs

Interventions

Intervention 1: Intervention group: Treatment group received a daily supplement of vitamin E (400 IU) in combination of selenium (200µg). Intervention 2: Placebo group: Take two placebo tablets daily,

Eligibility

Sex/Gender

Male

Age

20 Years to 55 Years

Inclusion criteria

Inclusion criteria: Infertile men with asthenoteratozoospermia (ATZ) with normal morphology lower than 4% and total motility lower than 40%

Exclusion criteria

Exclusion criteria: Cases with leukocytospermia (>1×106 WBC/mL) Oligospermia Varicocele Cancer Endocrine disorders Genital tract infection Autoimmune disease Cryptorchidism Smoking or alcohol consumption Patients who received chemotherapy or radiotherapy Patients who received recent antioxidant intake Azoospermia

Design outcomes

Primary

Measure	Time frame
Sperm concentration. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: According to WHO 2010 guidelines.;Sperm motility. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: According to WHO 2010 guidelines.;Sperm morphology. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Using Papanicolaou staining and and according to WHO 2010 guidelines.;Sperm viability. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Using Eosin Nigrosin staining and according to WHO 2010 guidelines.;Sperm apoptosis. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: By flow cytometry and according to WHO 2010 guidelines.;Sperm protamine deficiency. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: CMA3 staining and fluorescence microscopy and according to WHO 2010 guidelines.;Intracellular superoxide anion. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: By flow cytometry.;HSPA2 positive sperm. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: By flow cytometry.;NOX positive sperm. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: By flow cytometry.	—

Measure

Time frame

Sperm concentration. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: According to WHO 2010 guidelines.;Sperm motility. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: According to WHO 2010 guidelines.;Sperm morphology. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Using Papanicolaou staining and and according to WHO 2010 guidelines.;Sperm viability. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Using Eosin Nigrosin staining and according to WHO 2010 guidelines.;Sperm apoptosis. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: By flow cytometry and according to WHO 2010 guidelines.;Sperm protamine deficiency. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: CMA3 staining and fluorescence microscopy and according to WHO 2010 guidelines.;Intracellular superoxide anion. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: By flow cytometry.;HSPA2 positive sperm. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: By flow cytometry.;NOX positive sperm. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: By flow cytometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParvin Sabeti

Sanandaj University of Medical Sciences

ivfyazd@yahoo.com+98 87 3366 4645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026